These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21251901)

  • 41. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.
    Ichinohe T; Watanabe I; Ito S; Fujii H; Moriyama M; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T; Hasegawa H
    J Virol; 2005 Mar; 79(5):2910-9. PubMed ID: 15709010
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine.
    Ainai A; Ichinohe T; Tamura S; Kurata T; Sata T; Tashiro M; Hasegawa H
    J Med Virol; 2010 Mar; 82(3):476-84. PubMed ID: 20087927
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
    Lee YS; Lee KA; Lee JY; Kang MH; Song YC; Baek DJ; Kim S; Kang CY
    Vaccine; 2011 Jan; 29(3):417-25. PubMed ID: 21087689
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.
    Wang D; Christopher ME; Nagata LP; Zabielski MA; Li H; Wong JP; Samuel J
    J Clin Virol; 2004 Dec; 31 Suppl 1():S99-106. PubMed ID: 15567101
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epidermal powder immunization: cellular and molecular mechanisms for enhancing vaccine immunogenicity.
    Chen D; Burger M; Chu Q; Endres R; Zuleger C; Dean H; Payne LG
    Virus Res; 2004 Jul; 103(1-2):147-53. PubMed ID: 15163503
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
    Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J
    Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice.
    Hovden AO; Cox RJ; Madhun A; Haaheim LR
    Scand J Immunol; 2005 Oct; 62(4):342-52. PubMed ID: 16253121
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The protection of ferrets against influenza by immunization with a split influenza vaccine.
    Brady MI; Furminger IG
    Dev Biol Stand; 1975; 28():167-72. PubMed ID: 1126566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine.
    Hagenaars N; Verheul RJ; Mooren I; de Jong PH; Mastrobattista E; Glansbeek HL; Heldens JG; van den Bosch H; Hennink WE; Jiskoot W
    J Control Release; 2009 Dec; 140(2):126-33. PubMed ID: 19712713
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice.
    Madhun AS; Haaheim LR; Nilsen MV; Cox RJ
    Vaccine; 2009 Dec; 27(52):7367-76. PubMed ID: 19781678
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.
    de Vries JJ; Bungener L; Ter Veer W; van Alphen L; van der Ley P; Wilschut J; Huckriede A
    Vaccine; 2009 Feb; 27(6):947-55. PubMed ID: 19059296
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intranasal immunization of ferrets with commercial trivalent influenza vaccines formulated in a nanoemulsion-based adjuvant.
    Hamouda T; Sutcliffe JA; Ciotti S; Baker JR
    Clin Vaccine Immunol; 2011 Jul; 18(7):1167-75. PubMed ID: 21543588
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immune enhancing properties of the novel Matrix-M™ adjuvant leads to potentiated immune responses to an influenza vaccine in mice.
    Magnusson SE; Reimer JM; Karlsson KH; Lilja L; Bengtsson KL; Stertman L
    Vaccine; 2013 Mar; 31(13):1725-33. PubMed ID: 23384754
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nontoxic outer membrane vesicles efficiently increase the efficacy of an influenza vaccine in mice and ferrets.
    Shim SM; Song EJ; Song D; Lee TY; Kim DJ; Nam JH; Gwin Jeong D; Lee CK; Kim SH; Kim JK
    Vaccine; 2017 Jun; 35(30):3741-3748. PubMed ID: 28576571
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cationic liposomes as adjuvants for influenza hemagglutinin: more than charge alone.
    Barnier Quer C; Elsharkawy A; Romeijn S; Kros A; Jiskoot W
    Eur J Pharm Biopharm; 2012 Jun; 81(2):294-302. PubMed ID: 22487055
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhancing effects of pertussis toxin B oligomer on the immunogenicity of influenza vaccine administered intranasally.
    Oka T; Honda T; Morokuma K; Ginnaga A; Ohkuma K; Sakoh M
    Vaccine; 1994 Nov; 12(14):1255-8. PubMed ID: 7856288
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunity to influenza in ferrets. X. Intranasal immunization of ferrets with inactivated influenza A virus vaccines.
    McLaren C; Potter CW; Jennings R
    Infect Immun; 1974 Jun; 9(6):985-90. PubMed ID: 4830530
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety, immunogencity, and efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferrets.
    Chen GL; Lamirande EW; Jin H; Kemble G; Subbarao K
    Virology; 2010 Mar; 398(1):109-14. PubMed ID: 20034647
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel vaccinological evaluation of intranasal vaccine and adjuvant safety for preclinical tests.
    Sasaki E; Kuramitsu M; Momose H; Kobiyama K; Aoshi T; Yamada H; Ishii KJ; Mizukami T; Hamaguchi I
    Vaccine; 2017 Feb; 35(5):821-830. PubMed ID: 28063707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.